Angiotensin II and renal fibrosis
- PMID: 11566946
- DOI: 10.1161/hy09t1.094234
Angiotensin II and renal fibrosis
Abstract
Angiotensin (Ang) II, the main peptide of the renin angiotensin system (RAS), is a renal growth factor, inducing hyperplasia/hypertrophy depending on the cell type. This vasoactive peptide activates mesangial and tubular cells and interstitial fibroblasts, increasing the expression and synthesis of extracellular matrix proteins. Some of these effects seem to be mediated by the release of other growth factors, such as TGF-beta. In experimental models of kidney damage, renal RAS activation, cell proliferation, and upregulation of growth factors and matrix production were described. In some of these models, blockade of Ang II actions by ACE inhibitors and angiotensin type 1 (AT(1)) antagonists prevents proteinuria, gene expression upregulation, and fibrosis, as well as inflammatory cell infiltration. Interestingly, Ang II could also be involved in the fibrotic process because of its behavior as a proinflammatory cytokine, participating in various steps of the inflammatory response: Ang II (1) activates mononuclear cells and (2) increases proinflammatory mediators (cytokines, chemokines, adhesion molecules, nuclear factor kappaB). Finally, Ang II also regulates matrix degradation. These data show that drugs controlling this complex vasoactive peptide are probably one of the best ways of avoiding fibrosis in progressive renal diseases.
Similar articles
-
Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.Kidney Int Suppl. 2002 Dec;(82):S12-22. doi: 10.1046/j.1523-1755.62.s82.4.x. Kidney Int Suppl. 2002. PMID: 12410849
-
Renal tubular hypertrophy induced by angiotensin II.Semin Nephrol. 1997 Sep;17(5):448-54. Semin Nephrol. 1997. PMID: 9316213 Review.
-
Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms.Nephrologie. 1998;19(7):451-6. Nephrologie. 1998. PMID: 9857383 Review.
-
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.Kidney Int. 2005 Mar;67(3):799-812. doi: 10.1111/j.1523-1755.2005.00145.x. Kidney Int. 2005. PMID: 15698420 Review.
-
Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats.Hypertension. 1999 Aug;34(2):279-84. doi: 10.1161/01.hyp.34.2.279. Hypertension. 1999. PMID: 10454454
Cited by
-
Therapeutic potential of targeting the renin angiotensin system in portal hypertension.World J Gastrointest Pathophysiol. 2013 Feb 15;4(1):1-11. doi: 10.4291/wjgp.v4.i1.1. World J Gastrointest Pathophysiol. 2013. PMID: 23596549 Free PMC article.
-
Mechanism of Chaihuang-Yishen formula to attenuate renal fibrosis in the treatment of chronic kidney disease: Insights from network pharmacology and experimental validation.Heliyon. 2024 Aug 8;10(16):e35728. doi: 10.1016/j.heliyon.2024.e35728. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39220918 Free PMC article.
-
NF-kappaB and chemokine-cytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin-angiotensin system.Urol Res. 2005 Nov;33(5):358-67. doi: 10.1007/s00240-005-0484-4. Epub 2005 Nov 13. Urol Res. 2005. PMID: 16284884
-
Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis.Thorax. 2006 Jul;61(7):604-10. doi: 10.1136/thx.2005.051946. Epub 2006 Apr 6. Thorax. 2006. PMID: 16601095 Free PMC article.
-
Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways.Am J Pathol. 2003 Jul;163(1):355-66. doi: 10.1016/S0002-9440(10)63659-0. Am J Pathol. 2003. PMID: 12819040 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous